Sanderling Ventures

PreciThera, Inc. is a biotechnology company based in Montreal, Canada, dedicated to developing biological therapeutics for rare bone diseases. Founded in 2016, the company focuses on heterogeneous genetic disorders that primarily lead to bone dysfunction. By leveraging computational technology alongside a comprehensive understanding of disease pathology, PreciThera aims to create targeted therapies that address both skeletal and extraskeletal symptoms in affected patients. The company seeks to enhance treatment options through innovative approaches, including traditional protein replacement therapies, to improve the quality of life for individuals with these rare conditions.

Liphorus Pharmaceuticals Inc. is a Montreal-based company founded in 2014 that specializes in the development of pharmaceuticals aimed at treating hypercholesterolemia. The company focuses on small molecules and therapeutic antibodies that target PCSK9, a protein involved in cholesterol regulation. Through innovative research agreements, including collaborations with the IRCM, Liphorus works to create and validate compounds that enhance the reduction of LDL cholesterol levels. Their approach aims to provide patients with effective oral administration options for managing their cholesterol levels.